AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22551107
Drug: EDP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP plus mitotane (first-line therapy, no second-line therapy)
Trial: 22551107
Drug: Streptozocin plus
RxNorm normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Streptozocin plus mitotane (first-line therapy, no second-line therapy)
Trial: 18245143
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone support (control)
Trial: 9890407
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg nicorandil
Trial: 9890407
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg nitroglycerin
Trial: 1804576
Drug: Pirenzepine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (50 mg b.i.d. perorally)
Trial: 26894591
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg/kg (Group-2)
Trial: 26894591
Drug: Sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4 mg/kg (Group-4)
Trial: 26894591
Drug: Sugammadex 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 16 mg/kg (Group-16)
Trial: 11083260
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Trial: 11083260
Drug: Single DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single DMARD therapy with or without prednisolone
Trial: 11083260
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with DMARDs
Trial: 9122365
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg thiamine daily for 2 months
Trial: 8452112
Drug: Fast neutron
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast neutron radiation (mixed-beam treatment schedule)
Trial: 30096702
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus cisplatin (SP): S‐1 40 mg/m2 for 21 days plus cisplatin 60 mg/m2 (q5w)
Trial: 30096702
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus cisplatin (XP): capecitabine 1000 mg/m2 for 14 days plus cisplatin 80 mg/m2 (q3w)
Trial: 25730028
Drug: IMRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT plus DC-CIK immunotherapy (study group, N = 34)
Trial: 25730028
Drug: IMRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT plus DC-CIK immunotherapy (study group)
Trial: 21594659
Drug: 150 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 µg clonidine
Trial: 18833168
Drug: Proflusak (fluoxetine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proflusak (fluoxetine)
Trial: 14959468
Drug: Nifedipin‐retard (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipin‐retard (40 mg/day, 20 mg twice a day)
Trial: 14959468
Drug: Nifedipin‐retard (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipin‐retard (20 mg/day) in combination with metoprolol (100 mg/day, 50 mg twice a day)
Trial: 16913498
Drug: Dan Shao
RxNorm normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dan Shao Tang (DST) and western medicine
Trial: 8025366
Drug: Balanced amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced amino acid solution (2510 kJ/24 h) for 6 h
Trial: 8025366
Drug: BCAA-enriched solution
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA-enriched solution (2510 kJ/24 h) for 6 h
Trial: 8025366
Drug: Balanced amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced amino acid solution (2510 kJ/24 h) for 6 h in healthy volunteers
Trial: 8025366
Drug: BCAA-enriched solution
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA-enriched solution (2510 kJ/24 h) for 6 h in healthy volunteers
Trial: 22115823
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 5 mg
Trial: 25391616
Drug: Treatment-focused genetic
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-focused genetic testing (TFGT)
Trial: 19499960
Drug: olmesartan/amlodipine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan/amlodipine 20 mg/5 mg
Trial: 19499960
Drug: olmesartan/amlodipine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan/amlodipine 20 mg/10 mg
Trial: 9506856
Drug: 25 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg T4 daily for two months (Group C)
Trial: 9506856
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg T4 daily for two months (Group D)
Trial: 9506856
Drug: 25 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg T4 daily for two months (Group A)
Trial: 9506856
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg T4 daily for two months (Group B)
Trial: 9506856
Drug: Thyroxine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine administration in group D (ThAab negative)
Trial: 24895144
Drug: Fostamatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib (100 mg bid)
Trial: 21562819
Drug: Leucine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine (250 mg/kg bm)
Trial: 20617176
Drug: On-treatment CD4+
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment CD4+ T-cell counts
Trial: 20617176
Drug: On-treatment HIV
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment HIV RNA levels
Trial: 12540386
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (4 g/d, consisting of 45% eicosapentaenoic acid and 39% docosahexaenoic acid as ethyl esters)
Trial: 12540386
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (4 g/d)
Trial: 12540386
Drug: Placebo (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn oil, 4 g/d)
Trial: 1856147
Drug: Amikacin given
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin given once daily (od)
Trial: 1856147
Drug: Amikacin given
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin given twice daily (bd)
Trial: 24481679
Drug: Doxorubicin (single-agent)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (single-agent)
Trial: 18317369
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (6 mg.kg body weight)
Trial: 11788381
Drug: L-Carnitine L-tartrate
RxNorm normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine L-tartrate (2 g L-carnitine/day)
Trial: 8835550
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with auranofin within one year of diagnosis of RA.
Trial: 8835550
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with slow acting antirheumatic drugs (SAARD) after 8 months compared to the early treatment group.
Trial: 7280753
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg) administered intramuscularly before repeat BTM and gamma camera studies
Trial: 7280753
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered before gamma camera studies
Trial: 21804414
Drug: Incisional negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative pressure wound therapy (NPWT) applied to closed surgical incisions (Group B)
Trial: 3699692
Drug: Euhydration (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euhydration (water intake of 20 ml/kg body weight)
Trial: 30832713
Drug: Jin's three-needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin's three-needle acupuncture (JTN) treatment
Trial: 30832713
Drug: JTN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTN treatment
Trial: 26965764
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (700 IU daily)
Trial: 21778259
Drug: Formoterol-budesonide combined
RxNorm normalized name: budesonide / formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol-budesonide combined treatment (18/640 μg daily)
Trial: 21778259
Drug: High-dose budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose budesonide treatment (1,600 μg daily)
Trial: 19747781
Drug: High-dose cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide, cisplatin, and BCNU (HD-CPB)
Trial: 19747781
Drug: Intermediate-dose CPB
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose CPB (ID-CPB)
Trial: 15929518
Drug: Sclerotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy plus octreotide (50 g/hr for 48 hours)
Trial: 10202728
Drug: Non-preserved balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-preserved balanced salt solution
Trial: 7604143
Drug: Progesterone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (mean daily dose of 1983 mg for 3 weeks)
Trial: 155322
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) in combination with nitrosourea (streptozotocin)
Trial: 155322
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) in combination with lactone (spironolactone)
Trial: 155322
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) in combination with both nitrosourea and lactone
Trial: 155322
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) in combination with nitrosourea (methyl CCNU)
Trial: 155322
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) in combination with lactone (testolactone)
Trial: 31840424
Drug: Advanced Routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced Routine (AR: Cleanser/Toner/Eye cream/Serum/Day & Night cream)
Trial: 31840424
Drug: Simple Routine
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Routine (SR: Cleanser & Day cream)
Trial: 30721143
Drug: Fenugreek transdermal
RxNorm normalized name: FENUGREEK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek transdermal patch 10% (FDP)
Trial: 30721143
Drug: Diclofenac dermal
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac dermal patch 1% (DP)
Trial: 17254029
Drug: Local paint-PUVA
RxNorm normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local paint-PUVA using 0.1% 8-methoxypsoralen gel
Trial: 15207885
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral 17beta-oestradiol (1 mg per day) combined with norgestimate (90 microg per day) for 3 consecutive days out of every 6-day treatment period (E2/iNGM)
Trial: 7652500
Drug: Cefotaxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (2 g) plus Metronidazole (500 mg)
Trial: 7652500
Drug: Imipenem/Cilastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/Cilastatin (1 g)
Trial: 7652500
Drug: Meropenem (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (500 mg)
Trial: 7652500
Drug: Imipenem/Cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/Cilastatin (500 mg)
Trial: 7249528
Drug: Chlorpheniramine (H1-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (H1-receptor antagonist)
Trial: 28456509
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g intravenous)
Trial: 28456509
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g intravenous) within 3 hours of giving birth
Trial: 25573527
Drug: Thalidomide (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100-300 mg daily) plus dexamethasone (12 mg/m2 on days 1-4 of a 28-day cycle)
Trial: 25573527
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus dexamethasone (12 mg/m2 on days 1-4 of a 28-day cycle)
Trial: 21294770
Drug: Sensor-augmented insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensor-augmented insulin pump therapy (n = 44)
Trial: 21294770
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (n = 39)
Trial: 19817242
Drug: G-glove
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G-glove
Trial: 18841284
Drug: Clopidogrel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel treatment (75 mg/d)
Trial: 8513522
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml bupivacaine, 0.125% in normal saline followed by the same amount of bupivacaine dissolved in 50% glycerin
Trial: 8513522
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml bupivacaine, 0.125% in 50% glycerin followed by the same amount of bupivacaine in normal saline
Trial: 3104371
Drug: Therapist-assisted relaxation
RxNorm normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapist-assisted relaxation treatment
Trial: 3104371
Drug: Self-help relaxation
RxNorm normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-help relaxation treatment
Trial: 31430297
Drug: ASO3B adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASO3B adjuvanted split virion vaccine
Trial: 31430297
Drug: Whole virion
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole virion non‐adjuvanted vaccine
Trial: 23018281
Drug: Amisulpride 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 800 mg/day (AMI-800 group)
Trial: 23018281
Drug: Amisulpride 400
RxNorm normalized name: amisulpride 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 400 mg/day (AMI-400 group)
Trial: 23023308
Drug: Esmolol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1.5 mg/kg iv 90 seconds before intubation
Trial: 23023308
Drug: Esmolol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1.5 mg/kg iv 3 minutes before intubation
Trial: 23023308
Drug: Esmolol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1.5 mg/kg iv 6 minutes before intubation
Trial: 17646693
Drug: Upper WBC
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper WBC quartiles (7.3-8.8; >=8.9 x 10(9)/l)
Trial: 15710939
Drug: HIV-1 vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 vaccine trial participants
Trial: 15710939
Drug: Participants believing
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants believing they received the vaccine
Trial: 15710939
Drug: Participants believing
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants believing vaccine efficacy was greater than 50%
Trial: 15710939
Drug: Participants believing
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants believing they received the vaccine and that vaccine efficacy was greater than 50%
Trial: 12189543
Drug: Epirubicin 20
RxNorm normalized name: epiRUBicin 200 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 20 mg m(‐2) for 3 weeks followed by 1 week of rest (1 cycle) and gemcitabine 1000 mg m(‐2) after Epirubicin on the same day
Trial: 12189543
Drug: Epirubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin and gemcitabine combination therapy
Trial: 10071291
Drug: Chemotherapy (tamoxifen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (tamoxifen, cisplatin, and dacarbazine)
Trial: 10071291
Drug: Chemoimmunotherapy (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy (chemotherapy followed by interferon alfa-2b and interleukin-2)
Trial: 7585854
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TAA) Aqueous nasal spray (220 micrograms once daily)
Trial: 2188493
Drug: Controlled-release isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release isosorbide-5-mononitrate 60 mg once daily
Trial: 2188493
Drug: Conventional isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional isosorbide dinitrate 20 mg 3 times daily
Trial: 31187937
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with 10% 5-aminolevulinic acid (ALA)
Trial: 31187937
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with 5% 5-aminolevulinic acid (ALA)
Trial: 28836954
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group 2 (IG2; n = 169) - therapists provided with feedback and clinical support tools, along with personalized treatment recommendations.
Trial: 24144472
Drug: F4/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F4/AS01 vaccine
Trial: 11421876
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate with amoxicillin and clarithromycin (RAC)
Trial: 11421876
Drug: Omeprazole with
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole with amoxicillin and clarithromycin (OAC)
Trial: 7948453
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication after 4 weeks
Trial: 7948453
Drug: Higher blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher blood levels of antipsychotic medication
Trial: 3129114
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with cimetidine 400 mg at bedtime
Trial: 3129114
Drug: Intermittent 'healing'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent 'healing' doses of cimetidine for 4 to 8 weeks
Trial: 21767934
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting injection risperidone (RLAI)
Trial: 21767934
Drug: Oral risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral risperidone (RisO)
Trial: 11101480
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation with oral rehydration therapy
Trial: 1612357
Drug: Sodium butyrate
RxNorm normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium butyrate (100 mmol/L)
Trial: 6734925
Drug: Difflam Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difflam Oral Rinse (benzydamine hydrochloride 0.15% w/v)